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Potent anti-cancer effects of 
less polar Curcumin analogues 
on gastric adenocarcinoma 
and esophageal squamous cell 
carcinoma cells
Fatemeh Alibeiki1, Naser Jafari1,2, Maryam Karimi3 & Hadi Peeri Dogaheh1
Curcumin and its chalcone derivatives inhibit the growth of human cancer cells. It is reported that 
replacement of two OH groups in curcumin with less polar groups like methoxy increases its anti-
proliferative activity. In this study, we explored benzylidine cyclohexanone derivatives with non-polar 
groups, to see if they possess increased anti-cancer activity. Novel 2,6-bis benzylidine cyclohexanone 
analogues of curcumin were synthesized, and their inhibitory effects on gastric adenocarcinoma 
(AGS) and esophageal squamous cell carcinoma (KYSE30) cancer cells were studied using an MTT 
assay. Cell apoptosis was detected by EB/AO staining, and cell cycle was analyzed by flow cytometry. 
Real-time PCR was performed for gene expression analysis. All synthesized analogues were cytotoxic 
toward gastric and esophageal cancer cells and showed lower IC50 values than curcumin. Treatment 
with 2,6-Bis-(3-methoxy-4-propoxy-benzylidene)-cyclohexanone (BM2) was 17 times more toxic than 
curcumin after 48 h incubation. All novel compounds were more effective than curcumin in apoptosis 
induction and cell cycle arrest at G1 phase. These results suggest that less polar analogues of curcumin 
have potent cytotoxicity in vitro. However, they need to be investigated further, especially with animal 
tumor models, to confirm their chemotherapeutic activity in vivo.
Curcumin is the most active component of rhizomes of Curcuma longa L. (also known as turmeric) and is clas-
sified in the family Zingiberaceae. It has been studied extensively due to its bio-functional properties, especially 
antioxidant, anticancer, anti-growth, antiarthritic, antiatherosclerotic, antidepressant, antiaging, antidiabetic, 
antimicrobial and anti-inflammatory activities1.
These activities have been attributed to methoxy, hydroxyl, α, β-unsaturated carbonyl moiety, or diketone 
groups in curcumin2.
Curcumin’s key mechanisms of chemotherapeutic action include inducing apoptosis; inhibiting proliferation, 
migration and invasion of tumors; and also weakening tumors to radiotherapy and chemotherapy. At a molecu-
lar level, this multi-targeted agent has been shown to exhibit anti-inflammatory activity through suppression of 
numerous cell signaling pathways including NF-κB, STAT3, NRF2, ROS, and COX23.
Several studies reported curcumin’s anti-cancer effects on gastrointestinal cancers, leukemia, breast cancer, 
genitourinary cancers, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, melanoma, neuro-
logical cancers, and sarcoma4, which demonstrate its potential capability to affect multiple targets.
Despite all these facts, the utility of curcumin is limited by its low bioavailability4. Thus, modifications of 
specific functional groups of curcumin that increase its bioavailability will increase its activity. Developing 
structural analogues of curcumin and synthesis of “man-made” curcumin analogues plays a role in the improve-
ment of its bioavailability. For instance, the natural analogues of curcumin such as dimethoxy-curcumin and 
bidemethoxy-curcumin were reported to have similar biological activity to curcumin5. Moreover, it has been 
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reported that chalcone and bis-chalcone derivatives have inhibited the growth of the human breast and colon 
cancer cell lines6.
In this study, our purpose was to explore efficacy of benzylidine cyclohexanone derivatives with methoxy, 
ethoxy, alkoxy, and propoxy groups, to see if they possess increased anti-cancer activity and to explore the mech-
anism of action of these analogues. In order to accomplish this, we developed a new series of 2,6-bis benzylidine 
cyclohexanone derivatives that indicate increased activity against gastric and esophageal cancer cells in vitro, 
compared to treatment with unmodified curcumin.
Methods
Synthesis of 2,6-bis benzylidine cyclohexanone derivatives. Benzaldehydes including 4-hydroxy 
benzaldehyde and 4-hydroxyl, 3-Methoxy benzaldehyde (5 mM) were dissolved in 25 mL solution of N,N-
Dimethylformamide (DMF) including potassium carbonate (K2CO3, 6 mM) as a catalytic base for 1 h at 80 °C. 
Afterward, individual reactions received one of the propargyl bromide, allyl bromide, or iodoethane. Then mix-
tures were heated and mixed for 24 h.
In order to extract benzaldehydes from DMF, 100 mL water and 50 mL ethyl acetate were added to mixtures 
and organic phases were isolated. Then compounds were dried on sodium sulfate, and finally ethyl acetate was 
evaporated.
Thin-layer chromatography (TLC) was conducted to determine the purity of products. The selected aromatic 
aldehydes were as follows: 4-propoxy benzaldehyde (3a), 3-methoxy, 4-propoxy benzaldehyde (3b), 4-Alkoxy, 
3-Methoxy benzaldehyde (3c), 4-ethoxy, and 3-methoxy benzaldehyde (3d) (Fig. 1).
2,6-bis benzylidene cyclohexanones (4a – 4e) were prepared by reacting 2 equivalents of aromatic aldehydes 
with 1 equivalent of cyclohexanone in the presence of ethanol and hydrochloric acid gas. Then the compounds 
were washed with cold ethanol and verified by TLC (Fig. 2). Finally, products were characterized and analyzed by 
13C-NMR, 1H-NMR and FT-IR.
Details of generated 2,6-bis benzylidene cyclohexanones including formula, structure, molecular weight, 
melting point, color and yield are presented in Table 1.
Cell Culture and Treatment. The human gastric adenocarcinoma (AGS) and esophageal squamous cell 
carcinoma (KYSE30) cell lines were provided by the Pasteur Institute of Iran. All reagents, chemicals and media 
were prepared and used freshly.
Cancer cells were grown in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS), penicillin 
(100 unit/ml) and streptomycin (100 μg/mL). Cells were cultured at 37 °C in a moistened atmosphere of 5% CO2 
and 95% air. Then, cells were trypsinized and plated in 96-well plates at a density of 1 × 104 cells per well in 150 μl 
medium, and incubated overnight. Next, cells were treated with a FBS-free medium containing 1 mg/ml of each 
compound by 1/4 serial dilutions. Then, plates were incubated for 24, 48, and 72 h. The cytotoxicity of curcumin 
derivatives was determined by an MTT assay.
MTT Assay. Culture media were removed 4 h before completion of the incubation time, then 200 μl of 
0.25 mg/ml MTT (Merck, Germany) was added to each well. Plates were incubated again for an additional 4 h in 
order to complete the incubation time. The supernatants were removed and 200 μl DMSO was added to the wells, 
and the plates were shaken for 10 min. The absorbance was measured at 540 nm by a plate reader (Synergy HT, 
BioTek).
Apoptotic Cell detection by EB/AO Staining. Cells were cultured in 96-well plates at a confluence of 
1 × 103 cells/well, incubated overnight and then treated with compounds in their 24 h specific IC50 doses. Then 
plates were centrifuged for 5 min (129 g, 1,000 rpm) at 4 °C. The ethidium bromide/acridine orange (EB/AO) dye 
mix (100 μg/mL ethidium bromide and 100 μg/mL acridine orange) was dissolved in PBS and 20 μl of the dye mix 
was added to wells. Cells were counted by an inverted fluorescence microscope (IX 71, OLYMPUS). Live cells 
Figure 1. Synthesized primary aromatic aldehydes.
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were determined by normal green color, which resulted from up-taking acridine orange (green fluorescence) and 
repelling ethidium bromide (red fluorescence).
Apoptotic cells display apoptotic bodies and perinuclear condensation of chromatin stained by ethidium bro-
mide, while live cells were identified as normal nuclear chromatin stained by acridine orange. Necrotic cells were 
detected by uniform ethidium bromide staining of the cells7. Images were captured with a digital camera (DP 71, 
OLYMPUS) equipped microscope. Experiments were done in triplicate, quantifying a minimum of 100 cells each 
time.
Flow Cytometric analysis of the Cell Cycle. Cells were cultured in 6-well plates at a confluence of 
1 × 106 cells/well. Cells were treated with compounds for 24 h with respective IC50 values. Then, cell cycle 
phases and DNA content were analyzed by flow cytometry. Briefly, cells were collected and fixed with ice eth-
anol 70% for 2 h. Fixed cells were centrifuged (300 g, 4 °C, 5 min) and washed with cold PBS, and then stained 
with diamidino-2-phenylindole (DAPI, 10 μg/mL, Triton X-100 0.1% v/v in PBS). Then, cells were filtered by a 
nylon mesh with a pore size of 30 μm. Cell cycle analysis was done using a flow cytometer (Partec CyFlow space, 
Germany). The distribution of cells in different cell cycle phases was assessed by Partec FloMax software.
mRNA expression analysis by qPCR. Cells were cultured in 6-well plates at a confluence of 2 × 105 cells/
well and kept at 37 °C in a moistened air of 5% CO2 overnight. Then, cells were treated for 48 h with respective 
IC50 values.
For RNA extraction from cells, Trizol reagent (Cat. No: 15596-026, Invitrogen, CA, USA) was used according 
to the manufacturer’s protocol. First-strand cDNA was generated from the cells’ extracted RNA by the RevertAid 
First Strand cDNA Synthesis Kit, Fermentas (Cat No: #K1621, Maryland, USA) according to manufacturer’s 
directions.
Primers (Bax, cyclin D1, VEGFA, Bcl-2, Caspase 3, c-myc, survivin and the Homo sapiens ribosomal protein 
L38 (RPL38) as a housekeeping gene) were designed using Primer Express 3.0 (PE Applied Biosystems, Foster 
City, CA, USA). See Table 2 for the details of primers used in quantitative real-time PCR. For accuracy and spec-
ificity, all primers were blasted in the NCBI website: http://www.ncbi.nlm.nih.gov/tools/primer-blast/. Primers 
were synthesized by the custom oligonucleotide synthesis service, Metabion (Martinsried, Germany).
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Figure 2. Synthesized 2,6-bis benzylidene cyclohexanones (4a – 4e also named BM1- BM5).
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Quantitative analysis was done using StepOne Real-Time PCR System (Applied Biosystems 7500, Foster City, 
CA, USA) with the PowerSYBR Green PCR Master Mix (Cat. No: 4309155, Applied Biosystems, Foster City, CA, 
USA).
Individual reaction mix contained an overall volume of 25 μl (master mix 12.5 μl, cDNA 3 μl, primer 3 μl, and 
H2O 6.5 μl). Thermocycling conditions were as follows: 50 °C for 2 minutes, 95 °C for 10 minutes, then 40 cycles 
of 95 °C for 30 seconds, 60 °C 30 seconds, and 72 °C for 30 seconds.
Relative quantities of target mRNA in test samples were measured and standardized to the housekeeping gene, 
RPL38 mRNA transcript level. The comparative Ct method was used to assess expression as previously described 
by Livak and Schmittgen8.
Statistical Analysis. IC50 values were analyzed using Sigma Plot 12 software. Values for the growth inhi-
bition study are presented as mean ± SD, except in figures where error bars represent standard error of mean 
(SEM).
Name Formula Structure MW Melting Point (°C) Color Yield
4a
2,6-Bis-(4-propoxy-
benzylidene)-
cyclohexanone (BM1)
C26H22O3 283.45 158–160.2 Yellow 78%
4b
2,6-Bis-(3-methoxy-4-
propoxy-benzylidene)-
cyclohexanone (BM2)
C28H26O5 442.50 162.9–164.2 Green 89%
4c
2,6-Bis-(4-allyloxy-3-
methoxy-benzylidene)-
cyclohexanone (BM3)
C28H30O5 446.53 182.9–184.3 Brown 85%
4d
2,6-Bis-(4-ethoxy-3-
methoxy-benzylidene)-
cyclohexanone (BM4)
C26H30O5 422.51 172.9–174.5 phosphorous 80%
4e
2,6-Bis-(4-hydroxy-3-
methoxy-benzylidene)-
cyclohexanone (BM5)
C22H22O5 366.41 145.5–147 Brown 87%
Table 1. Chemical characterization of the synthesized 2,6-bis benzylidene cyclohexanones including formula, 
structure, molecular weight, melting point, color and yield.
Target Forward primer Reverse primer Amplicon Size (bp)
Bax 5′-GCCCTTTTGCTTCAGGGTTTC 5′-CATCCTCTGCAGCTCCATGT 168
Cyclin D1 5′-GGCGGAGGAGAACAAACAGA 5′-TGTGAGGCGGTAGTAGGACA 181
VEGFA 5′-TGTCTAATGCCCTGGAGCCT 5′-GCTTGTCACATCTGCAAGTACG 175
Bcl-2 5′-CAGGATAACGGAGGCTGGGATG 5′-AGAAATCAAACAGAGGCCGCA 70
Caspase 3 5′-GCGGTTGTAGAAGAGTTTCGTG 5′-CTCACGGCCTGGGATTTCAA 101
c-myc 5′-CCCTCCACTCGGAAGGACTA 5′-GCTGGTGCATTTTCGGTTGT 96
Survivin 5′-TTCAAGGAGCTGGAAGGCTG 5′-AGCAATGAGGGTGGAAAGCA 151
RPL38 5′-TCACTGACAAAGAGAAGGCAGAG 5′-TCAGTGTGTCTGGTTCATTTCAGTT 88
Table 2. Primers used in quantitative PCR and the amplicon sizes (bp: base pair).
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 2559  | DOI:10.1038/s41598-017-02666-4
Results
In order to assess the effect of synthesized compounds on cell proliferation, an MTT assay was conducted to test 
the inhibitory effect in three time points. After 24 h, all generated analogues were cytotoxic toward gastric and 
esophageal cancer cells and showed lower IC50 values than curcumin. As shown in Table 3 and Fig. 3, BM2 was 
4.6 times more toxic than curcumin toward gastric cancer cells. Similarly, esophageal cancer cells were more 
susceptible to BM2 and other synthesized compounds than curcumin (Supplementary Table S1). We observed 
the same pattern after 48 h, with BM2 17 times more toxic than curcumin (Table 3, and Fig. 4). Similarly, 72 h 
post treatment, all compounds were more effective than curcumin. Three curcumin analogues revealed IC50 with 
Nanogram/mL values (Table 3, and Fig. 5). Moreover, MTT assay on KYSE-30 cells confirmed our data and 
showed that synthesized compounds have cytotoxicity on esophageal cancer cells as well (Supplementary Table S1 
and Fig. S1). These data revealed that all synthesized analogues showed IC50 much less than curcumin in three 
time points.
In order to elucidate the mode of cell death, cells were stained with EB/AO, and apoptotic, necrotic, and live 
cells were counted. Synthetic compounds changed the morphology of treated cells to characteristic apoptotic 
cells. Nuclei of treated cells condensed and revealed fragmented chromatin and apoptotic bodies. As presented 
in Fig. 6B, treatment of AGS cells with synthesized BM2 triggered apoptotic cell death, which is characterized by 
fragmentation of nuclei. Quantification of treated and control cells revealed that synthesized analogues increased 
the number of apoptotic cells significantly compared to control cells (Fig. 6C and Fig. S2).
In order to verify that compounds trigger the apoptosis pathway, mRNA expression levels of important apop-
totic factors were analyzed. Treatment with synthesized compounds elevated BAX and caspase-3 mRNA levels, 
and down-regulated expression of cyclin-D1, VEGFA, Bcl-2, c-myc, and Survivin (Fig. 7 and Fig. S3).
In order to further confirm anti-proliferative effects, cell cycle distribution of the treated cells was evaluated. 
As displayed in Fig. 6, synthesized compounds were more potent than curcumin at arresting the cell cycle at G1 
phase. BM2 and BM3 were most effective at increasing the cell population at G1 phase. Simultaneously, analogues 
decreased the number of cells at S phase (Fig. 8 and Fig. S4).
Analogue 24 h 48 h 72 h
Curcumin 18.43 12.33 5.42
BM1 9.85 5.45 0.72
BM2 3.95 0.72 0.56
BM3 11.71 7.53 1.39
BM4 14.15 4.35 1.96
BM5 15.22 3.72 0.83
Table 3. IC50 values of synthetized 2,6-Bis Benzylidine cyclohexanone analogues in AGS cells that analyzed by 
MTT assay after 24 h, 48 h, and 72 h. Values are in µg/mL.
Figure 3. Inhibitory effect of synthesized compounds on AGS cells assessed with MTT assay at 24 h time point.
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Discussion
To date over 100 different clinical trials have been completed with curcumin which clearly shows its safety, toler-
ability, and effect against numerous chronic diseases in humans3.
Curcumin, a polyphenolic natural product, shows therapeutic function against a variety of diseases. These 
activities are attributed mainly to its chemical structure and unique physical, chemical, and biological prop-
erties. It is a di-feruloyl methane molecule [1,7-bis (4-hydroxy-3- methoxyphenyl)-1,6-heptadiene-3,5-dione)] 
containing two ferulic acid residues linked by a methylene connection. It has three key functional groups: an 
aromatic o-methoxy phenolic group, α, β-unsaturated β-diketo moiety and a seven carbon linker9. In this study 
we designed different analogues of curcumin with non-polar and hydrophobic groups (methoxy, propoxy, ethoxy, 
and allyloxy), in order to test the effect of less polar synthesized analogues on cancer cell proliferation and com-
pare them with the anti-cancer effect of curcumin.
Figure 4. Inhibitory effect of synthesized compounds on AGS cells assessed with MTT assay after 48 h time 
point.
Figure 5. Inhibitory effect of synthesized analogues on AGS cells determined by MTT assay after 72 h time 
point.
www.nature.com/scientificreports/
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Figure 6. EB/AO staining for detecting apoptotic cells. (A) Control un-treated AGS cells. (B) Representative 
micrograph of apoptotic cells treated with BM2 that are characterized with fragmented and condensed nuclei of 
cells. (C) Quantification of the cells with normal, necrotic and apoptotic representation.
Figure 7. Relative expression levels of Bax, cyclin D1, VEGFA, Bcl-2, Caspase 3, c-myc, survivin and RPL38 
mRNA in AGS cells. All Ct values were normalized with the homo sapiens ribosomal protein L38 (RPL38) as a 
housekeeping gene.
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Recently, it has been reported that replacement of two OH groups in curcumin with less polar groups like 
methoxy (OCH3) increases the anti-proliferative activity of arene-ruthenium(II) curcuminoid complexes in 
tumor cells. This report states that improved anti-cancer function is associated with apoptotic activity10. These 
findings are in accordance with our results: by decreasing curcumin polarity, its in vitro anti-tumor activity 
increases significantly. Our various experimental results on esophageal and gastric cancer cells revealed that all 
synthesized analogues of curcumin are more toxic than curcumin: after 48 h treatment in gastric cancer cells, 
BM2 was 17 times more toxic than curcumin (Fig. 4).
Very recently it is reported that curcumin triggered cell cycle arrest at G1 phase, and reduced the cell pop-
ulation in S phase in p53-mutated human colon adenocarcinoma cells11. These finding are in agreement with 
our data, which demonstrate that synthesized analogues increase cell population at G1 phase and decrease cell 
population at S phase (Fig. 8).
The same study reports that curcumin induced apoptosis in p53-mutated COLO 320DM colon adenocar-
cinoma cells11. Our novel synthesized compounds were more effective than curcumin at triggering apoptosis 
(Figs 6 and 7 and Supplementary Figs S2–S4).
It has been reported that curcumin induced apoptosis in leukemia cells by PARP-1 cleavage, increased level 
of caspase-3, apoptosis inducing factor (AIF) and down-regulation of Bcl212. Another study suggested that den-
drosomal curcumin (DNC) significantly increased cell population in SubG1, induced apoptosis and up-regulated 
p21, BAX, and Noxa in hepatocarcinoma cell lines. While the expression of Bcl-2 decreased13. Moreover, it 
has been reported that a curcumin analogue ((1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione) 
down-regulated cyclin D1 and activated Caspase 3, 8 and 9 in lung adenocarcinoma (A549), leukemia (K562) 
and colon cancer (SW480) cells14. Another study showed that curcumin suppressed VEGF secretion from tumor 
cells both in vitro and in vivo, and subsequently could block VEGF-VEGFR2 signaling pathways15. It has been 
evidenced that curcumin combination with resveratrol synergistically induced apoptosis in cigarette smoke 
condensate transformed breast epithelial cells by increasing Bax/Bcl-xL ratio, Cytochrome C release, cleaved 
product of PARP and caspase 3. Whereas, this combination decreased c-myc and cyclin-D116. Nevertheless, it 
has been demonstrated that dimethoxy curcumin (DMC) as a non-polar and lipophilic analogue of curcumin 
down-regulating survivin and upregulating E-cadherin in colon cancer cells which significantly suppressed the 
growth and migration of cells17.
Our novel synthesized compounds potentially up-regulated Bax and caspase-3 and down-regulated 
anti-apoptotic players (Fig. 7).
Cyclin D1 is one of the G1 phase related regulatory factors18; its down-regulation in our results verifies poten-
tial effect of novel analogues on cell cycle arrest at G1 phase (Fig. 8).
Taken together, novel synthetic 2,6-bis benzylidine cyclohexanone analogues were more efficient than cur-
cumin to inhibit cancer cell proliferation, trigger apoptosis, and arrest cell cycle at G1 phase. These data suggest 
that cyclohexanone analogues of curcumin could be promising anti-cancer agents to consider for more research 
on animal tumor models and even human clinical trials.
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